Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.
Type 5 adenovirus (Ad5) is a human pathogen that has been widely developed for therapeutic uses, with only limited success to date. We report here the novel finding that human erythrocytes present Coxsackie virus-adenovirus receptor (CAR) providing an Ad5 sequestration mechanism that protects against systemic infection. Interestingly, erythrocytes from neither mice nor rhesus macaques present CAR. Excess Ad5 fiber protein or anti-CAR antibody inhibits the binding of Ad5 to human erythrocytes and cryo-electron microscopy shows attachment via the fiber protein of Ad5, leading to close juxtaposition with the erythrocyte membrane. Human, but not murine, erythrocytes also present complement receptor (CR1), which binds Ad5 in the presence of antibodies and complement. Transplantation of human erythrocytes into nonobese diabetic/severe combined immunodeficiency mice extends blood circulation of intravenous Ad5 but decreases its extravasation into human xenograft tumors. Ad5 also shows extended circulation in transgenic mice presenting CAR on their erythrocytes, although it clears rapidly in transgenic mice presenting erythrocyte CR1. Hepatic infection is inhibited in both transgenic models. Erythrocytes may therefore restrict Ad5 infection (natural and therapeutic) in humans, independent of antibody status, presenting a formidable challenge to Ad5 therapeutics. "Stealthing" of Ad5 using hydrophilic polymers may enable circumvention of these natural virus traps.
Carlisle
Robert C
RC
Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom. Robert.carlisle@clinpharm.ox.ac.uk
Di
Ying
Y
Cerny
Anna M
AM
Sonnen
Andreas F-P
AF
Sim
Robert B
RB
Green
Nicola K
NK
Subr
Vladimir
V
Ulbrich
Karel
K
Gilbert
Robert J C
RJ
Fisher
Kerry D
KD
Finberg
Robert W
RW
Seymour
Leonard W
LW
D000258:Adenovirus Infections, Human / Q000097:blood / Q000276:immunology; D000260:Adenoviruses, Human / Q000276:immunology* / Q000378:metabolism / Q000502:physiology; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology / Q000502:physiology; D001665:Binding Sites; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D004912:Erythrocytes / Q000276:immunology* / Q000378:metabolism* / Q000821:virology; D005260:Female; D019073:HT29 Cells; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D008822:Mice, Transgenic; D008954:Models, Biological; D011951:Receptors, Complement / Q000276:immunology*; D011991:Receptors, Virus / Q000276:immunology*; D014407:Tumor Cells, Cultured; D038301:Virus Inactivation
C568771:CLMP protein, human; C568772:CLMP protein, mouse; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D011951:Receptors, Complement; D011991:Receptors, Virus